Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market

SHANGHAI - Having received approval from China's State FDA for Januvia (sitagliptin), Merck Sharp & Dohme announced March 21 that it has launched the dipeptidyl peptidase-4 inhibitor for Type 2 diabetes and joined the race to compete in China's $300 million oral diabetes drug market